Valuation: Celltrion, Inc.

Market Cap 40,545B 26.84B 23.54B 21.73B 20.08B 38.07B 2,570B 38.83B 261B 102B 1,258B 101B 98.58B 4,366B P/E 2026 *
27.4x
P/E 2027 * 24.3x
Enterprise Value 42.59B 28.19M 24.73M 22.83M 21.09M 39.98M 2.7B 40.78M 274M 107M 1.32B 106M 104M 4.59B EV / Sales 2026 *
8.05x
EV / Sales 2027 * 6.79x
Free-Float
58.37%
Yield 2026 *
0.41%
Yield 2027 * 0.45%
Manager TitleAgeSince
Chief Executive Officer 42 26/03/2021
Chief Executive Officer 65 20/03/2015
President 50 13/02/2026
Director TitleAgeSince
Director/Board Member 75 -
Chairman 68 -
Director/Board Member 61 01/04/2005
Change 5-day change 1-year change 3-year change Capi.($)
+0.73%+2.05%+2.42%+9.00% 49.42B
-0.36%+1.21%+420.77%+619.10% 40.34B
-2.13%+0.29%+23.91%-6.01% 34.01B
-2.29%+3.83%+23.48%+59.26% 33.56B
+3.82%+3.51% - - 17.22B
-2.62%-2.13%+64.96%+125.87% 15.19B
-2.17%+6.65%+104.31%+102.15% 13.96B
+0.84%-2.23%+13.23%+18.72% 13.36B
-1.93%-5.47%+9.16%-30.02% 12.68B
Average -0.68%+0.86%+82.78%+112.26% 25.53B
Weighted average by Cap. -0.63%+1.32%+100.84%+143.11%

Financials

2026 *2027 *
Net sales 5,293B 3.5B 3.07B 2.84B 2.62B 4.97B 336B 5.07B 34.11B 13.25B 164B 13.16B 12.87B 570B 6,181B 4.09B 3.59B 3.31B 3.06B 5.8B 392B 5.92B 39.83B 15.48B 192B 15.36B 15.03B 666B
Net income 1,518B 1B 881M 813M 752M 1.42B 96.19B 1.45B 9.78B 3.8B 47.07B 3.77B 3.69B 163B 1,698B 1.12B 986M 910M 841M 1.59B 108B 1.63B 10.94B 4.25B 52.67B 4.22B 4.13B 183B
Net Debt 2,041B 1.35B 1.19B 1.09B 1.01B 1.92B 129B 1.95B 13.15B 5.11B 63.32B 5.07B 4.96B 220B 1,427B 945M 829M 765M 707M 1.34B 90.48B 1.37B 9.2B 3.57B 44.28B 3.55B 3.47B 154B
Logo Celltrion, Inc.
Celltrion Inc is a Korea-based company mainly engaged in the production and sale of bio pharmaceuticals. The Company operates its business through two segments. The Bio Pharmaceutical segment produces and sells protein therapeutics such as anticancer drugs. In addition, this Segment develops monoclonal antibodies(mABs) that are used to treat chronic autoimmune diseases such as arthritis and severe diseases such as breast and colon cancer. The Chemical Pharmaceutical segment is mainly engaged in the manufacture and sale of chemical drugs. In addition, the Segment sells bio drugs, and provides services such as data analysis. The Company's main products include liver and bowel medicines and other generics. The main products sold by the Company include autoimmune disease treatment agents, anti-malignant tumor drugs and other products. The Company sells its products in domestic and overseas markets such as Europe and the United States.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
A